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ABSTRACT  
PART A is a research protocol which describes the background and proposed methodology of this 
systematic review and meta-analysis. This section details the quantitative and qualitative 
methods to be used when analysing the effect of Aloe in the treatment of patients with irritable 
bowel syndrome (IBS).  
PART B is an extended literature review which expands on some of the topics raised in the 
background section of the protocol. A more in-depth explanation of the epidemiology of IBS, is 
presented, as well as the strengths and limitations of current treatment options in order to 
understand the context around the proposed research.    
PART C presents this research in the form of a journal manuscript in a format suitable for 
submission to Plos ONE.  This manuscript includes a background to the research followed by the 
results section which is then discussed. Lastly, implications for clinical practice are posited and 
suggestions for further research are offered. 
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ABBREVIATIONS AND DEFINITIONS 
Abbreviations 
 
FGIDs Functional Gastrointestinal Diseases 
GSRS Global Symptoms Rating Scale 
HRQoL Health-related Quality of Life 
IBS Irritable Bowel Syndrome 
IBS-C IBS with Predominant Constipation 
IBS-D IBS with Predominant Diarrhoea 
IBS-M IBS with Mixed Bowel Habits 
IBS-U Unclassified IBS Subtype 
RCT Randomized Control Trial 
 
 
Definitions 
 
Aetiology The cause or set of causes of causation of a disease or condition [1]. 
Antispasmodic A pharmaceutical drug or agent that suppresses muscle spasms [1]. 
Bulking agent 
Non-nutritive substances that reduce the amount of strain produced 
during defecation by promoting peristalsis and maintaining fecal 
softness [1]. 
Laxative 
Pharmaceutical drug or agent that promotes bowel loosening and 
movement [1]. 
Pathogenesis The manner of development of a disease [2]. 
Rome Criteria 
A set of guidelines that have been used to indicate the criteria needed to 
be met before IBS can be diagnosed [3].   
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REGISTRATION 
This systematic review and meta-analysis protocol has been published in the PROSPERO International 
Prospective Register of systematic reviews [4], registration number CRD42018082663. 
1. BACKGROUND 
Functional gastrointestinal disorder (FGID) is a term used for defining several variable combinations 
of recurrent or chronic gastrointestinal (GI) symptoms that lack an identified underlying 
pathophysiology.  In the absence of an objective biomarker, the identification and classification of 
FGIDs has been based on symptoms [5]. 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal 
pain and changes in bowel habit in the form of constipation, diarrhoea or both [6–8].  IBS is 
categorized depending on the predominant stool pattern: Constipation-predominant (IBS-C), 
Diarrhoea-predominant (IBS-D), Mixed pattern (IBS-M), or unclassified phenotype (IBS-U) [8].  
It is estimated that IBS affects between 5-15% of the world’s population; making it one of the more 
common gastrointestinal (GI) disorders [8,9]. In addition, it is reported that as much as 30% of visits 
to gastroenterologists belong to patients showing IBS-related symptoms[6]. IBS patients have shown 
similar or worse health-related quality of life (HRQoL), compared to chronic diseases like diabetes 
mellitus [8].  As a functional gastrointestinal disease (FGID), IBS is said to represent a major part of 
the work load of primary care physicians and gastroenterologists, and is one of the leading causes for 
referral to emergency care units, thus draining substantial amounts of healthcare resources [10].    
IBS largely remains an unexplained disorder of the gut function, as multiple disease pathways can 
lead to identical clinical phenotypes [11].  These include changes in the gut microbiome, impaired 
sensitivity and motility, increased permeability, psychological distress and alterations in the brain-gut 
4 
 
axis [9,11]. Food also seems to play a key role, as exacerbation of symptoms after meals is reported 
by most IBS patients.  Also, self-reported food intolerance is associated with reduced quality of life 
and higher symptom severity scores [11].  
Conventional medical treatment is purely based on the predominant symptoms, and includes 
treatment with antispasmodics and laxatives to treat constipation-related symptoms, as well as 
bulking agents in the case of diarrhoea.  More severe cases of the disorder may require psychological 
therapies, anxiolytics or even antidepressants [7,9,11].  However, these treatment options have 
shown limited efficacy, and many patients resort to complementary and alternative medicine (CAM) 
therapies, despite lack of evidence to support their use.  These include dietary interventions and 
herbal preparations including peppermint oil and Aloe [7,12,13]. 
Aloe is a plant genus that produces latex and gel [7].  The gel is extracted from the leaf, and it is this 
substance that is most used as a treatment.  Previous research in rats suggests its laxative and anti-
inflammatory actions may have a beneficial effect in the treatment of constipation-predominant IBS 
[14,15], and research conducted on humans suggests it may be effective in treatment of 
inflammatory bowel disease symptoms [16,17].  Clinical trials have also been carried out to assess 
the effectiveness of Aloe in treating IBS symptoms among humans subjects, however the evidence of 
its effects is limited and contradictory [13].  To date, the effectiveness of Aloe in treating IBS 
symptoms in clinical trials has not been systematically studied.  Therefore, the aim of this study is to 
evaluate the effect of Aloe on symptoms associated with Irritable Bowel Syndrome in adults. 
2. AIMS AND OBJECTIVES 
2.1.  AIMS 
To evaluate the effect of Aloe on symptoms associated with Irritable Bowel Syndrome (IBS) in adults. 
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2.2.  OBJECTIVES 
To summarize the existing evidence on the contribution of Aloe to improved health outcomes among 
adult patients diagnosed with IBS and where possible, identify potential factors that may influence 
this response. 
3.  REVIEW QUESTION 
Among adults diagnosed with irritable bowel syndrome, is the consumption of Aloe, compared with 
placebo, associated with improved health outcomes? 
4.  METHODS 
The reference for methods employed in this study is the Cochrane Handbook of Systematic Reviews 
of Interventions [18].   
4.1. Criteria for considering studies in this review 
4.1.1. Type of studies 
The systematic review is to include randomised controlled trials (RCTs), non-randomised controlled 
trials, retrospective and prospective cohort studies, and controlled before-and-after (CBA) studies.  
4.1.2. Types of participants 
Participants include adults ≥18 years of age who have been diagnosed with irritable bowel syndrome 
(IBS) based on relevant diagnostic criteria, including Manning criteria or Rome iterations [3,19].  
4.1.3. Types of interventions/ exposures 
For this systematic review, the term ‘Aloe’ will be used to denote Aloe Vera, Aloe Ferox or any species 
in the Aloe genus in their natural form or in any commercially-available form.  This study authors 
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include Aloe in its different forms as a therapeutic intervention to address symptoms related to IBS.  
This includes patients who received conventional medications in addition to Aloe, as well as those 
not taking any conventional medication but seeking treatment in the form of complementary and 
alternative medicine (CAM) therapies. 
4.1.4. Types of outcome measures 
The primary outcome measure is patients’ self-reported quality of life or improvement of symptoms.  
The outcome measures for IBS will be based on the Gastrointestinal Symptoms Rating Scale (GSRS) 
or similar rating scales, as well as Quality of Life validated tools such as EuroQol (EQ5D), Short Form 
12 (SF12) and Short Form 36 (SF36) quality of life questionnaires.  This choice of primary outcome is 
in keeping with most studies reported to date. 
4.2. Search strategy 
A comprehensive search strategy will be developed to search both published and unpublished 
literature.  This will include peer-reviewed journal articles, conference proceedings and grey 
literature. The strategy will include free-text as well as Medical Subject Headings (MeSH) terms 
relating to IBS and Aloe literature.  Table 1 shows the main search terms to be used, which will be 
adapted to suit individual databases using applicable syntax and vocabulary. 
4.2.1. Electronic searches 
This study will use the following databases for its electronic searches: Medline/PubMed, 
EMBSAE/Scopus, EBM reviews, Global Health and International Pharmaceutical Abstracts, CINAHL, 
Web of Science, Mednar, Cochrane Central Register of Control Trials, Pan African Clinical Trials 
Register, clinicaltrials.gov, World Health Organization Library Information System (WHOLIS) and 
Ebscohost.  Grey literature will be searched as well. 
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Table 1: Terms used for searching databases (Comprehensive search strategy available in 
Appendix  
Subject Key search terms 
#1: Irritable Bowel 
Syndrome 
Intestinal diseases, colonic diseases, irritable bowel syndrome, 
gastrointestinal motility, irritable colon, peristalsis, constipation, 
diarrhea, feces, stool, abdominal pain, bloating, defecation, laxatives, 
bulking agent, dysmotility, visceral hypersensitivity, spastic colon, Rome 
criteria  
#2: Aloe 
Xanthorrhoeaceae, Aloe, Asphodelaceae, Aloeaceae, Aloeandongensis, 
Aloedent, Aloe emodin, aloe*, emodin, barbaloin 
4.2.2. Selection of studies for inclusion  
A screening form will guide the evaluation of articles identified by the search strategy against the 
inclusion criteria.  Two review authors (FF and IS), working independently, will screen the titles and 
abstracts of all studies identiﬁed through the literature searches for eligibility.  Thereafter, the two 
authors will independently assess the full-text of each article for eligibility.  Any discrepancies will be 
resolved through discussion and consensus, and in case of persistent disagreements, a third author 
(MS), will be consulted.  All the reasons for studies being excluded from the systematic review will be 
documented by the reviewers. 
5. DATA EXTRACTION AND MANAGEMENT  
Two authors (FF and IS) will extract descriptive and outcome data for each included article using a 
standardised data extraction form.  Any discrepancies will be resolved by discussion and consensus.  
In case no consensus is reached, a third author (MS) will arbitrate.  The ﬁnal data will be analysed 
with Review Manager V.5.3 statistical software [20], and will be cross-checked by a second author 
(ME) to ensure that there are no data entry errors. References will be managed using the Mendeley 
citation manager [21]. 
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The data extraction will include the following key eligibility criteria: 
1. Study design 
2. Type of participants 
3. Form of treatment 
4. Details of outcome 
6. RISK OF BIAS AND QUALITY APPRAISAL 
Two reviewers (FF and IS) will apply the Cochrane tool for Risk of Bias assessment tool for randomized 
controlled trials and similar tool for other applicable study designs.  The criteria used to assess the 
risk of bias in RCTs includes allocation concealment, blinding of participants and study personnel, 
random sequence generation, incomplete outcome data, selective reporting of outcomes and overall 
risk of bias, in accordance with the methods used by the Cochrane Collaboration.  The same tool will 
be used to assess the quality of evidence for the contribution of Aloe and its derived products towards 
improving quality of life or overall symptoms. Two reviewers (FF and IS) will independently assign the 
grade scores and compare results as per the process for the recording of previous aspects of the 
study. Discrepancies will be resolved by consensus discussion between the two primary reviewers, 
with arbitration by a third reviewer as necessary.  
6.1. Dealing with missing data 
Where necessary, the authors of the selected studies will be contacted for missing data.  If the 
authors are not able to respond, missing data will be indicated in the review. 
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7.  DATA ANALYSIS AND SYNTHESIS 
7.1. Subgroup analyses  
Subgroup analyses will be performed by IBS diagnosis subtypes: Constipation variety (IBS-C) and 
diarrheal variety (IBS-D), as well as by method used to measure self-reported quality of life or 
improvement of symptoms.  
7.2. Sensitivity analyses 
Where possible, sensitivity analyses will be conducted.  It will first be determined whether the study 
design (randomized vs. nonrandomised study) could inﬂuence the meta-analysis results. Secondly, 
the model of the statistical method will be evaluated to determine if it could change the results (i.e. 
fixed-effects vs. random effects model). The impact of excluding studies with a high-risk bias on the 
results will be determined, with emphasis on loss to follow-up, allocation concealment and blinded 
outcome assessment (with a cut-off of 25% loss to follow-up).  
7.3. Assessment of heterogeneity 
Outcomes of interest will be expressed as risk ratios and their respective 95% confidence intervals 
(CI) and p-values will be calculated for dichotomous outcomes, while for continuous data, mean 
differences and standard deviations (SDs) will be calculated.  If outcomes are measured using 
different scales, these will be recoded into dichotomous measures based on study authors’ definition 
of patients’ response to treatment. 
Heterogeneity will be assessed by examining types of interventions, types of participants, and types 
of outcomes in each study with the intention to pool data and estimate effect sizes using a ﬁxed-
effects model only from studies in which outcomes are judged to be homogeneous.  Alternatively, 
the random-effects model will be used if outcomes or interventions are not judged to be 
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homogeneous.  Statistical heterogeneity in each meta-analysis will be assessed using the χ2 test and 
quantiﬁed using the I2 statistic.  The ﬁndings will be discussed as a narrative summary if the 
heterogeneity remains signiﬁcant.  Included studies will be summarised in tables to highlight the main 
existing evidence.  
7.4. Assessment of reporting biases 
In order to assess risk of publication bias, funnel plots will be used to examine asymmetry, provided 
there are 10 or more studies included.  If evidence is found of small study effects, publication bias 
will be considered as a possible explanation.  A sensitivity analysis will be undertaken if plots suggest 
treatment effects may not be from a symmetric distribution. 
8. REPORTING OF THIS SYSTEMATIC REVIEW  
The ﬁndings of this review will be reported in several ways. The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) ﬂow diagram will be used to summarise the process 
of study selection. A κ statistic will be used to assess agreements between the full-text screening, 
data extraction and risk of bias assessment by the authors. Where necessary, the authors will adapt 
the reporting to ensure that all items relevant to this review are included. 
9. ETHICS  
Ethics will not be required for this study as it utilises existing public health data.  The authors will 
obtain a waiver letter from the university health research ethics committee. 
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1.   INTRODUCTION 
Functional gastrointestinal disorder (FGID) is a term used for defining several variable combinations 
of recurrent or chronic gastrointestinal (GI) symptoms that lack an identified underlying 
pathophysiology.  In the absence of an objective biomarker, the identification and classification of 
FGIDs has been based on symptoms [1].   
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal 
pain, and changes in bowel habit including diarrhoea, constipation or both [2–4].  IBS is categorized 
according to the predominant stool pattern: Constipation-predominant (IBS-C), Diarrhoea-
predominant (IBS-D), Mixed pattern (IBS-M), or unclassified phenotype (IBS-U) [3]. The severity, 
frequency and duration of symptoms can range from negligible to incapacitating, and often affect the 
usual activities of affected individuals. According to its latest definition based on the Rome IV criteria, 
symptom onset should occur at least 6 months before diagnosis, and symptoms should be present 
for at least the last three months [5].  
Although IBS has no impact on mortality, IBS subjects tend to show similar or worse health-related 
quality of life (HRQoL) when compared to chronic diseases like diabetes mellitus [3].  IBS is reported 
to account for 12% of all visits to primary care physicians, and as much as 30% of visits to 
gastroenterologists [6].  Like other FGIDs, IBS can also cause indirect costs in the form of absenteeism 
[3]. In Europe, costs to industry through absenteeism related to IBS are estimated between USD 500 
– 1,200 per patient annually [6]. 
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2. EPIDEMIOLOGICAL ASPECTS OF IBS 
2.1. Aetiology and pathophysiology of IBS 
The causes of IBS are not fully elucidated, largely due to the lack of specific biomarkers.  IBS largely 
remains an unexplained disorder of the gut function, since multiple disease pathways can lead to 
identical clinical phenotypes [7].  These include impaired motility and sensitivity, increased 
permeability, changes in the gut micro-biome, psychological distress and alterations in the brain-gut 
axis [7,8]. Food also seems to play a key role, as most IBS patients report onset or exacerbation of 
symptoms after meals.  Also, self-reported food intolerance is associated with reduced quality of life 
and higher symptom severity scores [7]. 
IBS is a lifelong condition where incidence seems to increase with age [9].  A bidirectional relationship 
is thought to exist between the psyche and the gut as studies on the natural history of FGIDs have 
shown that IBS patients are particularly prone to develop psychological problems [10].  Psychological 
distress is considered to be a risk factor for IBS, although causality has not yet been established.  
Depression, anxiety, neuroticism as well as emotional and physical abuse, as well as difficulties coping 
with life events are reported to be frequent among IBS patients [10]. Two population-based cohort 
studies have shown that those with psychological distress at baseline were at greater risk of 
developing IBS, suggesting a brain-gut pathway through the stress response.  Likewise, these same 
studies have shown that those with IBS are at greater risk of new onset psychological distress [7]. 
Post-infectious gastroenteritis has also been identified as a risk factor for IBS:  Among 45 studies in a 
meta-analysis, the rate of post-infectious IBS following enteritis turned out to be higher with parasitic 
or protozoan infestation (42%) than with bacterial infection (14%).  Overall, the risk of IBS was 4 times 
higher in those with infectious enteritis compared to the controls [11]. 
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Dietary factors are also thought to play a role in the determination of the syndrome, as most IBS 
patients report the onset or exacerbation of their symptoms after having a meal [8].  Gluten and 
lactose sensitivities, as well as ingestion of excessive amounts of fermentable carbohydrates are 
thought to play a role in the pathogenesis of IBS [10]. 
Genetic factors are also thought to play a role.  Family cohort and case-control studies indicate that 
those with a family member with IBS have 2 to 3 times greater risk of developing IBS compared to 
those people without an affected family member.  Genetic case-control studies have identified single 
nucleotide polymorphisms (SNP) that may be linked to IBS and functional dyspepsia (FD), however 
evidence of causality is missing in most cases as replication of these studies has been inconsistent [7].  
The different likely pathophysiological mechanisms make IBS a heterogeneous disorder that poses a 
challenging task in the development of effective treatments [3]. In summary, the causes of IBS appear 
multifactorial and have not been completely understood.   
2.2. Prevalence of IBS  
Worldwide, IBS prevalence varies significantly between countries.  A meta-analysis shows a pooled 
estimate of international IBS prevalence of 11.2%, with variation by geographic region.  The lowest 
prevalence occurs in South Asia (7.0%), and the highest in South America (21%), with considerable 
heterogeneity between the studies [6].  Women are at greater risk of IBS compared to men, as well 
as individuals older than 50 years. IBS prevalence rates are 1.5 to 3 times higher among women 
compared to men [2].  The effect of socioeconomic status has not yet been clearly described [12].   
Because of different diagnostic criteria being used, high frequency of symptoms, lack of specific 
biomarkers and point of onset, epidemiological studies of IBS can be very challenging, with measures 
of occurrence such as prevalence being largely dependent on diagnostic criteria used [4]. 
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2.3. IBS Sub-types 
Depending on the predominant stool pattern, IBS is categorized as a diarrhoea-predominant (IBS-D), 
constipation-predominant (IBS-C), mixed-pattern (IBS-M), or unclassified sub-type (IBS-U) [5,10].  
Stool form and consistency is defined based on the Bristol stool scale, and used as a proxy measure 
for intestinal transit time [13,14].  The IBS sub-types can be defined as follows: 
IBS with predominant constipation (IBS-C):  This is defined as >25% of bowel movements with Bristol 
stool form types 6 or 7 and <25% of bowel movements with Bristol stool form types 1 or 2 [5].  IBS-C 
is usually distinguished from chronic idiopathic constipation (CIC) by the presence of abdominal pain 
in the former. However in reality, the two disorders can often overlap in the same individual [10].  
IBS with predominant diarrhoea (IBS-D): This is defined as <25% of bowel movements with Bristol 
stool form types 6 or 7 and >25% of bowel movements with Bristol stool form types 1 or 2. 
IBS with mixed bowel habits (IBS-M):  Defined as >25% of bowel movements with Bristol stool form 
types 1 or 2 and >25% of bowel movements with Bristol stool form types 6 or 7. 
Unclassified subtype (IBS-U):  Describes those patients who meet diagnostic criteria for IBS but 
whose bowel habits cannot be categorized into any of the three previous groups [10]. 
2.4. Diagnosis of IBS 
Despite IBS being a common problem, there is no “gold standard” or objective diagnosis method in 
the absence of biological markers.  Therefore, IBS diagnosis has traditionally been one of exclusion 
[15].  Recently however, it has been recommended that a positive diagnosis of IBS should be made 
based on symptoms (using the Rome IV criteria), exclusion of alarm features and judicious 
biochemical testing [16]. 
The first widely-used diagnostic criterion was the result of a study aimed at enabling the identification 
of symptoms that could help doctors distinguish IBS from other functional gastrointestinal disorders.  
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The results of this study were published in 1978, and became known as the “Manning criteria”.  Later 
efforts at fine-tuning diagnosis methods took place in the 1980s through the work of Dr Aldo Torsoli, 
professor of gastroenterology at Rome University.  Dr Torsoli used a Delphi approach to select experts 
from around the world to develop a consensus criterion for the diagnosis of IBS and other FGIDs.  This 
work would later result in the publication of a book titled “The Functional Gastrointestinal Disorders: 
Diagnosis, Pathophysiology, and Treatment”, which would later be regarded as the Rome I criteria.  
Rome I would be refined in various iterations over the years, resulting in Rome II in the year 2000, 
Rome III in 2006 and Rome IV in 2016  [17].  In the absence of biological markers, these various 
iterations of the Rome guidelines have been used to indicate the criteria needed to be met before 
IBS can be diagnosed.  Table 1 presents a summary table that summarizes these diagnostic tools. 
Table 1 – Summary table of Manning and Rome criteria used frequently in epidemiological studies for 
identification of cases.  Adapted from [5,9]. 
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Although the validity of the Rome criteria in its various iterations has been studied, conventional 
measurements of sensitivity and specificity have not been used in the absence of biomarkers.  
Instead, sensitivity has been assessed through cases that have presented and have already been 
diagnosed, and specificity has been assessed through those with organic gastrointestinal disease.  It 
has been shown that these criteria have modest specificity to diagnose IBS for those with 
gastrointestinal disease (about 70% specificity) although it is believed that this can be increased to 
90% if patients with symptoms such as weight loss, rectal bleeding and anaemia can be investigated 
more extensively and IBS can be ruled out by exclusion.  It is reported that sensitivity across the 
criteria used can vary from 40% to 90%, depending on the skill and level of experience of the clinician 
[2].  Given the inconsistent application of diagnostic criteria over the years, the definition of cases in 
epidemiological studies has been problematic. This lack of uniformity in diagnostic criteria is said to 
partially account for the variability in prevalence studies [2].   
3. TREATMENT OF IBS 
Traditionally, treatment of IBS has started with the identification of predominant symptoms and their 
severity.  Patients should be counselled on lifestyle recommendations that include exercise, 
managing stress and increasing the intake of fluids, and reassured that IBS follows a benign course 
[18].   
3.1. Conventional treatment 
3.1.1. Non-pharmacological treatment 
Non-pharmacological treatment is first offered, especially among patients that don’t show severe 
enough symptoms that can affect their quality of life [19].   
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Diet modifications 
IBS patients are often advised to avoid foods that produce gas such as onions, beans, celery, carrots 
and prunes.  Also, a lactose-free diet should be prescribed if patients are lactose-intolerant. 
Fermentable Oligo-, Di-, Mono-saccharides And Polyols (FODMAPs) are short chain carbohydrates 
that are poorly absorbed in the small intestine.  A FODMAP-low diet is commonly recommended and 
includes the avoidance of high-fructose corn syrup, wheat, honey, cherries, mangoes and pears.  IBS 
patients are initially asked to eliminate FODMAPs in their diets for a period between 6-8 weeks and 
then to restart intake of foods that are high in fermentable carbohydrates so as to determine the 
tolerance to particular fermentable carbohydrates [19]. 
Physical exercise 
In addition to improving muscle and bone conditioning and reducing the risk of cardiovascular 
disease, physical activity has also shown to be beneficial for IBS in reducing anxiety and depression.  
A clinical trial with 75 patients showed that increased physical activity over a 12 week period reduced 
the symptoms related to IBS [20]. 
3.1.2. Pharmacological treatment 
Irritable bowel syndrome, as it is currently labelled, is believed to consist of a group of conditions 
with different pathophysiological mechanisms.  This heterogeneity complicates drug development 
and when interpreting study results.  Thus it is important to link outcomes to specific 
pathophysiological mechanisms, such as anxiety-related dysfunctions, visceral hypersensitivity, 
constipation, etc. [3]. Conventional pharmacological treatment of IBS is purely symptomatic, and 
includes treatment with laxatives, bulking agents and antidiarrheal medication, depending on the 
sub-type.  More severe cases of the disorder may require anxiolytics or antidepressants [7,8,21].  
Regardless of IBS sub-type, antispasmodics such as hyosciamine and dyclomine can be also be dosed 
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as needed and have been shown to be beneficial in relief of symptoms in the short term.  
Antispasmodics relieve abdominal pain brought on by IBS by relaxing the smooth muscle of the gut 
[5].   
Laxatives 
Patients with constipation-predominant IBS (IBS-C) may benefit from specific treatment of 
constipation through the use of laxatives.  Commonly used laxatives have an osmotic mechanism of 
action, being poorly absorbed in the gut, they increase the water content in stools, making them 
easier to pass as well as increasing peristalsis in the colon [22]. Common osmotic laxatives include 
milk of magnesia, lactulose and polyethylene glycol (PEG).  PEG is more commonly considered a safe 
initial treatment of constipation symptoms, as it has shown few side effects.  PEG is used to increase 
the osmotic pressure of fluids in the intestinal lumen, which helps cleanse the GI tract [5,19].  
Although it has shown its efficacy in improving bowel movements in clinical trials, PEG has not been 
more effective than placebo in reducing bloating or abdominal pain, bloating or other symptoms 
related to IBS [22].   Both PEG and lactulose work by increasing water in the intestinal lumen to 
decrease intestinal transit time, although lactulose may cause abdominal pain from fermentation in 
the intestinal lumen [22].  Among laxative-resistant IBS-C patients, chloride-secretion stimulating 
drugs such as linaclotide and lubiprostone are thought to have analgesic effects, reducing abdominal 
pain while at the same time improving stool patterns [3]. A systematic review and meta-analysis 
found linaclotide to be moderately effective in improving IBS-C symptoms, with diarrhoea being a 
major side effect, and recommended further studies to evaluate linaclotide’s long‐term safety and 
efficacy for patients with for IBS‐C [23]. 
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Bulking agents 
It is not uncommon for physicians to advise the intake of bulking agents in the form of fibre 
supplements to address altered bowel habits and abdominal pain.  Ispaghula husk, also known as 
psyllium, as well as bran, are common fibre supplements.  Fibre increases luminal osmotic load, 
influences the micro-biome and attracts water which results in an increased biomass, which in turn 
helps decrease colonic transit time.  Although commonly used, its benefit in addressing common IBS 
symptoms has not yet been established.  A Cochrane systematic review and meta-analysis did not 
find a significant effect on abdominal pain or global improvement of symptoms [3,24].  
Antidiarrheals 
The most common anti-diarrheal medication used for treatment of IBS-D patients is Loperamide.  
Loperamide is a synthetic opioid that acts on the intestinal muscles to prolong intestinal transit time 
and inhibit peristalsis [3], and has proven to be effective in improving IBS-D symptoms:  A meta-
analysis of four RCTs found Loperamide to be effective in decreasing stool frequency while at the 
same time improving stool consistency [25].  A dose of 2mg taken 45 minutes prior to a meal on a 
regular schedule is recommended [5,19,22].  Although it has been known to improve diarrhoea-like 
symptoms, it has not been shown to improve other symptoms like bloating and abdominal pain [25].  
Antispasmodics 
These are medications that can relax smooth muscle in the colon through anticholinergic mechanisms 
or calcium channel antagonists.  Common antispasmodics include dicyclomine, alverine, 
hyoscyamine, otilonium, scopolamine and pinaverium to mention a few.  Generally, antispasmodics 
have been used for their effects on improving gastrointestinal motility as a way to reduce abdominal 
pain associated with IBS [22].  Antispasmodics have been generally utilized for their effects on 
gastrointestinal motility to reduce abdominal pain.  A Cochrane systematic review and meta-analysis 
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of 29 trials suggests that some but not all antispasmodics may decrease abdominal pain.  Sub-group 
analyses in this study showed that pinaverium, trimebutine and a combination of dicyclomine and 
cimetripium were effective in improving symptoms.  Adverse effects of these agents include dizziness 
and dry mouth, as well as constipation.  Thus they should be prescribed to IBS-C patients with caution 
[22]. 
Antidepressants 
These have commonly been used as analgesics to treat chronic pain disorders, including FGIDs.  
Current guidelines endorse the use of tricyclic antidepressants (TCAs) and selective serotonin 
reuptake inhibitors (SSRIs).  It is believed that these agents act via centrally-mediated pathways that 
inhibit the sensation abdominal pain associated with IBS.  In addition to their positive effect on the 
mood of patients with psychiatric comorbidities like anxiety and depression, antidepressants are also 
thought to be useful in patients without depression, but who suffer from refractory and severe 
functional abdominal pain, albeit at a lower dosage.  The proposed mechanisms of action include 
antidepressants’ central pain-modulatory action, peripheral analgesic effects, improving sleep and 
influence on motility.  A Cochrane systematic review and meta-analysis reported antidepressants’ 
superiority over placebo in improving global IBS symptom scores, including those for abdominal pain.  
However, subgroup analysis showed a modest superiority of TCAs but not SSRIs in relieving 
abdominal pain [26].   
Despite extensive studies conducted, there remains a proven lack of efficacious pharmacological 
treatments for IBS.  In many instances, conventional treatment options for IBS have shown limited 
efficacy in improving patients’ quality of life, and it is not uncommon for individuals with IBS to seek 
complementary and alternative medicine treatments [27].   
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3.2.  Psychological therapies 
Cognitive behavioural therapy (CBT) 
It has been shown that when compared to healthy individuals, patients with IBS are more prone to 
suffer from anxiety and depression [28].  In addition, central processing mechanisms have been linked 
to the pathophysiology of IBS including visceral hypersensitivity and anxiety.  Thus, cognitive 
behavioural therapy is thought to help improve symptoms by targeting these processes.   CBT patients 
are taught to recognize and correct thoughts and behaviours that can undermine well-being or 
amplify their symptoms [29].  CBT has been demonstrated to reduce IBS symptoms in a meta-analysis 
of seven studies with 491 patients, with 57% of patients in the CBT group reporting improved 
symptoms compared with 39% in the placebo group (p<0.01), and a relative risk (RR) of 0.60 (95% CI 
0.42-0.87) [30].  Although CBT has demonstrated positive results in IBS patients, its labour-intensive 
nature and limited availability have limited their routine use among patients [3].  
Hypnotherapy 
Hypnosis has been defined as a state of consciousness that involves focused attention and a reduced 
peripheral awareness that is characterized by an enhanced capacity to respond to suggestions [31].  
Hypnotherapy then is the use of hypnosis for the treatment of medical or psychological disorders or 
concerns [31].  It is thought that by affecting certain parts of the brain that influence bowel 
movements or experience abdominal pain, hypnotherapy can provide benefits for IBS.  Hypnotherapy 
has been previously studied for treating IBS symptoms in various randomized controlled trials [32].   
A Cochrane collaboration systematic review and meta-analysis provided some evidence suggesting 
that hypnotherapy may be effective in treating IBS symptoms including abdominal pain in the short 
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term.  However the study authors advise caution with the results given the poor quality of studies 
and small sample size [32].   
3.3. Complementary and Alternative Medicine (CAM) treatment 
Complementary and Alternative Medicine (CAM) refers to a group of diagnostic and therapeutic 
disciplines that currently exist outside the institutions where conventional medical practices are 
taught and provided [33].  The terms complementary refers to when theories and practices of 
medicine that deviate from the conventional, are used in addition to standard medical practices, and 
alternative refers to when these treatments are used instead of conventional medicine [34]. 
CAM practices differ significantly from conventional medicine in terms of heterogeneity of 
treatments, perspectives on disease mechanisms and therapeutic measures. These practices are 
influenced by ethnic, cultural, social, regional, educational and economic factors [4].  Clinically 
speaking, it is estimated that more than 80% of the population in developing countries rely on herbal 
medicine for their primary care.  Aside from its well-known acceptance in India and China, the use of 
CAM therapies has also become common in European countries [35]. 
The efficacy of herbs and other forms of CAM to treat IBS has been a controversial topic. Physicians 
have often regarded CAM, particularly in the treatment of FGID, as having an “enhanced placebo 
effect” [4]. This has been thought to be the result of a heightened expectation of treatment efficacy 
due to the higher frequency of contacts with the therapist, which in turn results in a more positive 
relationship between the patient and the practitioner [4].  A study based on a single-blind RCT seems 
to support this notion, as it found that when conducting sub-group analyses within patients in the 
control group, the quality of the interaction between the patient and the practitioner did account for 
a significant difference in the way patients responded to treatment within this sub-group [36].  
However, two meta-analyses have found that the placebo response rate for both CAM and 
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conventional medicine is quite similar.  One meta-analysis of 73 RCTs using conventional medical 
treatments to treat IBS found that the pooled placebo response rate was 37.5% (95% CI 34.4–40.6%) 
[30].  Another meta-analysis of 19 RCTs using CAM treatments for IBS patients found a pooled effect 
of 42.6% (95% CI 38.0–46.5%) [37].   The considerable overlap in the response rate between the two 
studies suggests that the placebo effect may be independent of the type of therapy used, and that it 
may not be “enhanced” as initially thought by the use of CAM [37].  
3.3.1. Acceptance of CAM as treatment for FGIDs in western countries 
A study published in 1998 reported an increase use of CAM from 34% in 1991 to 42% in 1997 in the 
United States, 10% of which was for the treatment of digestive complaints.  Among this group, 
relaxation and herbal therapy was reported as the most sought-after therapy [38]. The use of CAM is 
particularly prevalent among patients with gastrointestinal issues, in particular women and 
individuals with symptoms of diarrhoea, constipation and bloating [39]. Complementary and 
alternative medicine (CAM) is reported to be even higher among patients that suffer from FGIDs.  
Dissatisfaction with conventional treatment and female gender continue to be valid predictors for 
the use of CAM.  In one study, as much as 70% of FGID patients have reported to discuss CAM use 
with their physicians with either neutral or encouraging responses, which may reflect a shift in 
attitudes among FGID patients to try CAM treatments, and among gastroenterologists who may even 
be open to consider probiotics as conventional treatment for some GI disorders [39,40]. 
CAM treatments for all digestive issues seem to be more popular in North America than in Europe, 
although it seems that in Europe the CAM industry is growing at a faster pace, with herbal remedies 
being the most widely-used form of CAM [41].  The use of herbal remedies appears to be particularly 
common in patients with IBS and IBD, which may be related to the refractory nature of these 
disorders as well as psychological factors. In the case of symptoms such as constipation, plant extracts 
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are commonly used as a symptomatic approach to its management.  The anthraquinones found in 
Aloe and Senna are known to have laxative properties [42].  Dietary fibre can also have a bulk-forming 
laxative effect as in the case of ispaghula husk, and it is not uncommon for people with constipation 
to self-prescribe with herbal remedies to treat constipation symptoms [41].   
3.3.2. CAM treatments for IBS commonly used 
In many instances, conventional treatment options for IBS have shown limited efficacy in improving 
patients’ quality of life [27], and many individuals with IBS have resorted to CAM treatments.  It has 
been reported that use of CAM treatments has been greater among patients with IBS than among 
patients with other FGIDs, and that as much as 50% of IBS patients would resort to CAM if 
conventional remedies failed [40,43]. 
Broadly speaking, CAM treatments for IBS include fibre, probiotics, cognitive behavioural therapy 
(CBT), hypnotherapy and herbal preparations including peppermint oil and aloes, with varying 
degrees of success [4,29,44,45]. 
Fibre 
It is not uncommon for IBS patients to be first advised to increase their fibre intake through diet.  
Psyllium, otherwise known as Ispaghula husk, is the ground seed coat of members that belong to the 
plant genus Plantago, and can also be found in whole grains, vegetables and fruits.  Psyllium has been 
employed as a bulking agent, by increasing the bulk of stools, which in turn encourages the bowels 
to move the stools through the colon, which ultimately helps relieve constipation [29].  Psyllium has 
been used as a dietary fibre to relief symptoms of both constipation and diarrhoea.   Another soluble 
fibre that has been used in the treatment of IBS is miller’s bran.  Also known simply as bran, it is the 
hard outer layer of cereal grain.  Bran is an integral part of whole grains and is commonly produced 
as a by-product when producing refined grains [45].  A systematic review and meta-analysis looking 
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to evaluate the effect of fibre in the treatment of IBS included both psyllium and bran.  When 
evaluating the effect of psyllium, 6 RCTs were included in one of the meta-analyses which showed a 
statistically significant effect on improvement of symptoms. The pooled relative risk was 0.78 (95% 
CI 0.63 to 0.96) [45].  The meta-analysis evaluating the effect of bran in the same study found no 
significant effect on improvement of symptoms with a relative risk of 1.02 (95% CI 0.82 to 1.27) [45]. 
Probiotics 
Probiotics are diet supplements that contain live bacteria or bacterial products.  When ingested, they 
have a beneficial effect by improving the gastrointestinal microbial balance.  Although probiotics’ 
precise mechanism of action is not yet known, it is thought that a disproportion of the gastrointestinal 
flora may play a role in the pathogenesis of IBS.  Thus it is thought that supplementing the 
gastrointestinal flora with the right types of microorganisms can improve the gut flora and promote 
health [22].  Probiotics may include formulations that include a single or mixed culture of 
microorganisms and are available in various preparations that include fermented milk drinks, 
capsules, pills, liquid supplements and powders.  Existing evidence suggests that certain strains of 
probiotics may improve visceral hypersensitivity and stimulate an anti-inflammatory response, which 
could in turn lead to improvement of IBS symptoms [46]. 
Herbal extracts commonly used to treat IBS 
The provenance of herbal medicine is extraordinarily diverse.  Indeed, its trans-cultural origin and 
centuries of continuing use suggest that at least some of its constituents are likely to be of therapeutic 
value.  This has become clear with the derivation from plants of a number of conventional drugs, 
including digoxin from foxgloves, aspirin from willow-bark, quinine from cinchona-bark and morphine 
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from the opium poppy [34].  Furthermore, pharmaceutical companies are now engaged in extensive 
screening programmes to identify and isolate therapeutically active agents from plants [34]. 
Every culture has explored and used plants for medicinal purposes.  The presence of several plants 
with medicinal properties in a Neanderthal tomb in Iraq suggests that herbs may have been used 
therapeutically for more than 60,000 years.  The first records come from China, where the Emperor 
Shen Nung compiled the Pen Tsao (The Great Herbal, or Chinese Materia Medica), around the year 
3,000 BC.  This book had many subsequent editions, and many of the thousand or more drugs 
described are still used in China today [47]. 
Peppermint oil 
As the name suggests, peppermint oil is essentially the oil extracted from the peppermint plant 
Mentha piperita, and has been traditionally used as an antispasmodic to treat upset stomach for 
centuries [29].  Peppermint oil appears to work by interfering with calcium channels which result in 
intestinal smooth muscle relaxation [22], and may provide short-term relief of abdominal pain.  A 
meta-analysis of  4 RCTs found that when compared to placebo, peppermint oil did contribute to 
overall symptom improvement, with a relative risk of 0.43 (95% CI 0.32 to 0.59), although with 
statistical heterogeneity between studies [45]. 
Senna 
Senna is a genus of flowering plants in the legume family Fabaceae.  This genus is native to the tropics 
and some temperate regions.  Senna has been historically used as a laxative by either ingesting the 
plant pods or as herbal tea made from the leaves.  It is considered a stimulant laxative as it induces 
peristaltic contractions, while at the same time acting on the intestinal mucosa by increasing water 
and electrolyte secretion [48,49].  At least three RCTs have compared the effect of senna with other 
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laxatives in the treatment of chronic constipation.  The three studies showed senna to be a better 
choice, especially when administered in combination with other agents.  Despite these findings, 
recommendations on the use of senna remain moderate based on the observation that excessive use 
can lead to Melanosis coli, which is considered a risk factor for developing cancer of the colon.  In 
addition to senna, another herbal laxative commonly used in treating IBS symptoms is the genus Aloe, 
which for the purposes of this study, a separate section is dedicated. 
4.  THE ALOE GENUS – HISTORY AND BACKGROUND 
Aloe is a plant genus that belongs to the Asphodelaceae family.  The origins of the genus have been 
traced back to Southern Africa, about 16 million years ago.  Aloes went through two major 
evolutionary radiations that have given rise to the extraordinary diversity of the species known today 
[50].  There are about 500 known species, with the majority found in southern Africa, Madagascar, 
the Arabian Peninsula and some western Indian Ocean islands. Of these, an estimated 160 are 
considered indigenous to South Africa [51].   
The name “Aloe” given to the genus is the result of one if its species, Aloe Vera, being so commonly 
used throughout history.  It is derived from the Arabic word alloeh, which means “shining bitter 
substance” while vera in Latin means ´truth´ [47].  Native to the Arabian Peninsula, the historical 
preference for the Aloe Vera species in Western culture seems to be due to its early introduction to 
cultivation and trade, as well as its proximity to important historical trade routes.  The resilience and 
ease of transport of this genus helps explain why Aloes can now be found in tropical and sub-tropical 
areas worldwide [47,50].   
Aloes have a well-documented history of use as medicine and have been used since ancient times.  
The earliest credible testimony concerning the human use of aloe has been found in Egypt dating 
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back to about 3,000 BC and consists of pictorial representations adorning funerary monuments and 
tombs [47].   The earliest evidence of the medicinal use of Aloe is found in the form of Mesopotamian 
clay tablets dated between 2,100 and 1,800 BC which describe in cuneiform the plant’s laxative 
properties [47].   Hippocrates of Kos, a physician from ancient Greece and often regarded as the 
“father of modern medicine”, described some medicinal properties of aloe, including the ability to 
promote hair growth, as a cure for tumours and for the relief of dysentery and stomach-ache [47].  
Later on, the widespread use of Aloe as a laxative appeared in the work of Greek physician Galen of 
Pergamon, dated between 129-216 AD [41].  Aloes are also one of only a few plants that appear in 
San rock paintings in South Africa, dating between 2,500 and 150 years [52,53].  An  ethno-botanical 
study has documented its usage by the Khoi-San in the Karoo region of South Africa as a purgative 
and laxative agent [54]. 
4.1.   Aloe species used for therapeutic purposes 
Two review studies focusing on the utility and bio-cultural value of the Aloe genus found that Aloe 
Vera, Aloe Ferox and Aloe Arborescens are the three species that make up the majority of 
documented medicinal and commercial applications [54,55].  Aloe Vera, also known as Aloe 
Barbadensis, has been cultivated worldwide for more than two centuries.  Aloe Ferox and Aloe 
Arborescens are originally from Southern Africa and are currently cultivated there,   supplying 
processed and unprocessed natural products to export markets, especially in Europe and Asia [54]. 
4.2.   Chemical composition of Aloes 
Aloes produce anthraquinone glycosides like aloin A and B (10-30%), sugars (25%), a resinous material 
(16-63%), mucilage (30%), fatty acids (cholesterol, b-sitosterol, campesterol), mucopolysaccharides 
acemannan and betamannan, glycoproteins including aloctins A and B, enzymes including 
cyclooxygenase and bradykininase, and other compounds including salicylic acid, lupeol, cinnamic 
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acid, urea nitrogen, sulphur, phenol, prostanoids, magnesium lactate, fibre etc. [42].  Of these 
compounds, some possess antiseptic properties (salicylic acid, lupeol, phenol and sulphur), 
immunostimulant properties (acemannan), anti-inflammatory properties (aloctins, b-sitosterol, 
cholesterol, campesterol, acemannan), and laxative properties (aloin A and B) [42].  
 
Aloes are perennial succulents, and characterized by long and thick fleshy leaves that are lance-
shaped, with spiny margins and a sharp apex [51].  The outer rind of the leaf consists mainly of 
structural components, and where anthraquinones and their glycosides are found.  The region in the 
outer pulp below the rind is where the bitter sap or latex is derived.  This latex consists mainly of 
anthraquinones, anthrones, flavonoids, chromones and pyrones.  The inner leaf pulp contains 
parenchyma cells which forms the gel.  This pulp is high in water content (approximately 99% for Aloe 
Vera species) and is high in the polysaccharide known as acemannan, as well as various phenolic 
phytochemicals such as alkaloids, anthrones, anthraquinones and flavonoids.  Enzymes, vitamins and 
minerals are also found in the pulp [55].  Figure 1 shows a schematic representation of the Aloe leaf 
morphology, and shows a leaf cross-section. 
 
Figure 1: Schematic representation of the Aloe leaf morphology and cross-section.  Adapted from [55]. 
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4.3. Aloe – In vitro and in vivo properties 
4.3.1.  Burn wound healing properties 
Aloe has shown to be effective in burn would healing in a four-arm comparative study conducted 
with guinea pigs. In this study, group 1 was given silver sulfadiazine (Silvadine), group 2 was given 
Aloe gel extract, group 3 received salicylic acid cream, and group 4 was given plain gauze occlusive 
resin only.  The study reported that after 50 days of treatment, of the four groups, the only statistically 
significant difference was found in the group of animals that received Aloe, in which wound healing 
time was significantly shorter (p<0.02) [56].  It is argued that these effects may be due to the 
increased rate of epithelialization brought about by the acemannan polysaccharide in its ability to 
stimulate fibroblasts and collagen synthesis, in addition to its anti-inflammatory, antimicrobial and 
moisturizing effects [57]. 
A study with human subjects conducted in Pakistan compared the effectiveness of Aloe gel with silver 
sulphadiazine (SSD) cream at 1% concentration, as burn wound dressing for second degree burns. 
Using systematic random sampling, 25 patients were assigned to each of the groups.  The study 
reported that the time needed for healing of burn wounds was remarkably shorter among those in 
the Aloe gel group compared to those receiving silver SSD.  In addition to being more cost-effective, 
the patients in the Aloe group also reported pain relief much earlier than those treated with SSD [58].   
In Thailand, Aloe gel has been formally included in the Thai Herbal Fundamental Public Health Drug 
List as a therapy for burn wounds [57].   
4.3.2.   Immunostimulant properties 
A carbohydrate found in Aloe gel known as Acemannan, has been evaluated for its antiviral activities 
and activation of immune responses.  One study set out to define the properties of Acemannan on 
dendritic cells in vitro.  After phenotypic analysis, the study confirmed that Acemannan could induce 
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maturation of immature dendritic cells and provided support to this claim [59].  Another study has 
shown that Acemannan can inhibit the replication of HIV-1 virus when the latter is introduced in vitro 
to blood cells of human subjects who have taken oral doses of Acemannan.  This suggests that it may 
have a prophylactic effect.  No adverse events were observed in the study [60]. 
Between 2008 and 2009, a preliminary study was conducted in Nigeria to evaluate the use of Aloe to 
treat HIV infection.  This controlled before-and-after (CBA) study included 10 young women with HIV 
infection and another 20 age-matched controls who were taking antiretroviral drugs.  During the 1-
year study period, their CD4 counts, general improvement and physical well-being were monitored.  
The results showed an average CD4 cell increase in the intervention group of 153.7 cells/µl, compared 
to 238.85 cells/µl for the controls (p=0.087), with no significant side effects in both groups.  Although 
the mean difference in CD4 count between the two groups was not statistically significant, the 
authors suggest that consumption of Aloe may help HIV-infected individuals in the tropics with 
significant cost-effectiveness potential [61].    
4.3.3.   Anti-inflammatory properties  
Aloes have been used topically by ancient and modern cultures for their wound healing and anti-
inflammatory properties.  In the West, Aloes have been used as an oral preparation for their anti-
inflammatory effects [62].  Aloes contain 3 malic acylated carbohydrates, which are Veracylglucans 
A, B and C.  These three compounds have demonstrated anti-inflammatory properties [51].   
A study reports that the anti-inflammatory action of Aloe gel in human colorectal mucosa in vitro may 
have a therapeutic effect in treating inflammatory bowel disease [62].  In a later study, the same 
author conducted a randomized control trial to evaluate the efficacy and safety of Aloe gel for 
treating ulcerative colitis.  This study found that after 4 weeks of treatment, when compared to the 
placebo group, the patients in the Aloe group showed decreased clinical colitis activity index and 
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histological scores (p=0.01 and p=0.03 respectively), pointing to therapeutic potential of Aloe in 
treating patients with inflammatory bowel disease [62].  
4.3.4.   Laxative properties 
The laxative properties of Aloe have been mainly attributed to the anthraquinones (mainly aloin) that 
are found in the yellow exudates of the leaves [63]. The laxative effect is believed to take place 
through water accumulation in the intestine via active Na+ transport or by water secretion due to 
aprostaglandin-dependent mechanism [47]. 
Previous research in rats suggests Aloe’s laxative actions may have a beneficial effect in the treatment 
of constipation-predominant IBS [64–66].  Aloe’s laxative properties have also been studied in 
patients with schizophrenia [67].  Antipsychotic treatment for schizophrenia is most often in the form 
of dopamine D2 receptor antagonists.  However, these medications often cause peripheral adverse 
effects including dry mouth and constipation.  In three different studies, Aloe gel was evaluated in 
the treatment of antipsychotic-induced constipation.  All three studies reported that Aloe was 
effective in relieving constipation symptoms [67]. 
4.3.5.   Aloe and its mechanism of action in the colon 
The laxative properties of Aloe have been mainly attributed to the anthraquinones (mainly in the 
form of aloin) that are found in the gel and yellow exudates of the leaves [63].  Once ingested, aloin 
is stable in the stomach, and the sugar moiety prevents its absorption in the gut and detoxification in 
the liver.  This protects the aloins from breakdown before they reach the colon and rectum [68].  Once 
the Aloins reach the large intestine, they behave like pro-drugs in that they are metabolized by gut 
bacteria into aloe-emodin, which is more readily absorbed and is ultimately responsible for Aloe’s 
purgative activity [47,69].  The laxative effect is thought to take place through accumulation of water 
in the intestine through active Na+ transport, or by water secretion caused by a prostaglandin-
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dependent mechanism [47,51].  A study that explored Aloe’s activities in the gastrointestinal tract in 
rats also suggests a relationship between an increase in intestinal water content caused by Aloe-
emodin, and stimulation of peristalsis [70–72]. 
4.3.6.   Traditional and conventional uses of aloe to treat digestive issues 
Although there is mention of Aloe gel being formally recognized in the Thai health system for topical 
use, no evidence has been found of Aloe being formally recognized as treatment for digestive issues.  
However, there is ample evidence of its use as a traditional and CAM treatment for these issues.  In 
addition to Aloe’s documented use as laxative dating back to at least 1,000 BC in Egypt and 
Mesopotamia, more recent evidence of its use is found in Africa, Europe and Asia [47].   
In southern Africa, Aloes remain one of the most popular components of the rich and diverse floral 
landscape.  The genus is of great importance from the taxonomic and ethno-medicinal perspectives 
[73].  Aloe bitters, also known as Cape Aloes, is the end product of extracting the bitter Aloe Ferox 
leaf exudate (also known as sap), which is heated until it crystallizes.  The Aloin, which is the main 
ingredient found in the crystals, has been known in South Africa and Europe as a potent laxative 
[51,66,68].  These crystals are orally consumed as laxative medicine in humans, and are also used for 
the same indication to treat cattle in Lesotho.  The literature shows numerous other ethno-medicinal 
applications of the Aloe Ferox sap in southern Africa, such as its use to relieve conjunctivitis, 
ophtalmia and other eye ailments by topical application of the leaf sap as eye drops [68]. 
Cape aloes is a component of Lewensessens, a bitter digestive tonic with a long history in South 
Africa, and also known as “Swedish bitters”, an early modern herbal preparation that has been 
widely used in Europe since the 1730s [74].  
Despite Aloe’s apparent popularity in treating constipation, not many studies have been conducted 
to evaluate the effectiveness of Aloe as a stand-alone herbal treatment for IBS-related symptoms.  
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The first known randomized controlled trial was published in 1991, where Aloe was used as part of 
an herbal preparation in combination with ispaghula husk and celandine in the ratio of 3:1:6 
respectively, for 28 days.  The study found that the mix was effective in treating functional 
constipation and constipation-predominant IBS symptoms [75].  Similarly in 2002, another study 
looked at a Tibetan herbal formula that contained Aloe for the treatment of constipation-
predominant IBS [76].  Like in a previous study, this study also found that the herbal concoction was 
effective in the treatment of IBS-C [76].  However, given that these are poly-herbal preparations 
where Aloe is used in addition to other compounds, it is difficult to attribute the effect solely to one 
single plant or ingredient. 
In addition to its use as laxative, Aloe is also thought to be useful in treating other IBS-associated 
symptoms, such as diarrhoea, bloating and abdominal pain.  Its anti-inflammatory properties are also 
thought to reduce gastrointestinal inflammation [62].   
The first known randomized control trial that examined a purer form of Aloe was published in 2006 
and looked at evaluating the effectiveness of an Aloe supplement in treating all IBS sub-types.  
Although the study failed to detect a significant effect when compared to placebo overall, a slight 
benefit was seen among the diarrhoea-predominant IBS patients while the treatment was being 
taken [21].  A later study in 2013 found  that Aloe did have a positive effect in reducing abdominal 
pain and flatulence among patients with IBS, however this study did not have a control group, which 
did not make it possible to determine if the relief of symptoms could be solely attributable to Aloe 
[77].   
Although clinical trials have been carried out to assess the effectiveness of Aloe in treating IBS 
symptoms, the evidence of its effects is limited and contradictory [78].  To date, the effectiveness of 
Aloe in treating IBS symptoms in clinical trials has not been systematically studied.  This presents an 
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opportunity to conduct a systematic review and meta-analysis to summarize the existing evidence on 
its contribution to improve IBS symptoms, and if possible, identify potential factors that may 
influence this response. 
5.   SUMMARY AND CONCLUSION OF THE LITERATURE REVIEW 
In conclusion, the reviewed literature highlights the complex and heterogeneous nature of IBS, where 
multiple pathways point to a brain-gut axis that influences and mediates commonly associated 
symptoms such as abdominal pain, bloating, constipation and diarrhoea.   Despite extensive research, 
evidence on the effectiveness of conventional pharmacological treatments for IBS patients is not yet 
conclusive.  
The refractory nature of the disorder, and in many cases, patients’ lack of satisfaction with 
conventional treatments prompts many to seek CAM therapies.  These include psychological 
interventions such as cognitive behavioural therapy and hypnosis.  Symptomatic treatments include 
the use of soluble fibre, probiotics and herbal extracts such as Peppermint oil, Senna and Aloe gel.   
The literature highlights the Aloe genus’ many chemical constituents and therapeutic potential.  
Various studies suggest its laxative and anti-inflammatory properties may be effective in treating IBS.  
However, to date, the effectiveness of Aloe in addressing IBS symptoms has not yet been 
systematically studied.   
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Consumption of Aloe to improve health outcomes in adults with irritable bowel 
syndrome:  A systematic review and meta-analysis.  
ABSTRACT 
Study aim: To evaluate the effect of Aloe on symptoms associated with Irritable Bowel Syndrome 
(IBS) in adults. 
Study objective: To summarize the existing evidence on the contribution of Aloe to improved health 
outcomes among adult patients diagnosed with IBS and where possible, identify potential factors that 
may influence this response. 
Design: Systematic review and meta-analysis of randomized controlled trials, non-randomised 
controlled trials, retrospective and prospective cohort studies, and controlled before-and-after (CBA) 
studies. 
Data sources: Medline, Scopus, EBM reviews, Africa-wide, CINAHL, Web of Science, Mednar, 
Cochrane Library, clinicaltrials.gov, World Health Organization Library Information System (WHOLIS), 
Ebscohost and Google Scholar up to August 2018. 
Review methods: Randomized controlled trials, non-randomised controlled trials, retrospective and 
prospective cohort studies, and controlled before-and-after (CBA) studies comparing Aloe in different 
preparations to placebo in adults with irritable bowel syndrome were eligible for inclusion.  Minimum 
duration of therapy considered was two weeks, and studies had to evaluate either a global 
assessment of cure or improvement in symptoms, or cure, or improvement in abdominal pain, after 
treatment.  A random effects model was used to pool the effect of therapy compared with placebo 
or no treatment. This was reported as the risk ratio (95% confidence interval) of those who responded 
to treatment versus those who responded to placebo. 
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Results: Compared with placebo, this systematic review found evidence for improvement in 
symptoms for Aloe-containing preparations in patients with IBS (relative risk (RR), 2.75; 95% 
confidence Interval (CI), 1.88 to 4.03, 5 studies, n=325; I2=0%).    In sub-group analyses, this finding 
was consistent amongst patients with constipation-predominant IBS (IBS-C) (RR, 3.41; 95% CI, 2.11 to 
5.51; 3 studies, n=199.  This finding was not replicated in the single study comparing Aloe with 
placebo in  patients with diarrhoea-predominant IBS (IBS-D) and mixed-pattern IBS (IBS-M). 
Conclusion:  Aloe-containing preparations were more effective than placebo in improving symptoms 
among all IBS sub-types combined.  In sub-group analyses, Aloe was more effective than placebo in 
the treatment of constipation-predominant IBS, however this was not the case with IBS-D and IBS-M 
sub-types. Given the variation in the formulae of Aloe preparations in the included studies, 
generalizability of this finding may be a challenge.  Thus, further research with adequately-powered 
studies using a standardised formulation for Aloe-containing preparations for IBS is advised. 
Keywords:  Irritable bowel syndrome, Aloe, constipation, laxatives.  
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1.   BACKGROUND 
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal 
pain and changes in bowel habit in the form of constipation, diarrhoea or both [1–3]. IBS is 
categorized depending on the predominant stool pattern: Constipation-predominant (IBS-C), 
Diarrhoea-predominant (IBS-D), Mixed pattern (IBS-M), or unclassified phenotype (IBS-U) [3].  
IBS is estimated to affect between 5-15% of the world’s population; making it one of the more 
common GI disorders [3,4]. In addition it is reported that as much as 30% of visits to 
gastroenterologists belong to patients showing IBS-related symptoms [5]. IBS patients have shown 
similar or worse health-related quality of life (HRQoL), compared to chronic diseases like diabetes 
mellitus[3].  As a functional gastrointestinal disease (FGID), IBS is said to represent a major part of the 
work load of primary care physicians and gastroenterologists, and is also one of the leading causes 
for referral to emergency care units, thus draining substantial amounts of healthcare resources [6].    
IBS largely remains an unexplained disorder of the gut function, as multiple disease pathways can 
lead to identical clinical phenotypes [7].  These include impaired motility and sensitivity, increased 
permeability, changes in the gut microbiome, psychological distress and alterations in the brain-gut 
axis [4,7]. Food also seems to play a key role, as most IBS patients report onset or exacerbation of 
symptoms after meals.  Food intolerance is in turn associated with reduced quality of life and higher 
symptom severity scores [7].  
Conventional medical treatment is purely symptomatic, and includes treatment with antispasmodics 
and laxatives to treat constipation-related symptoms, as well as bulking agents in the case of 
diarrhoea.  Severe cases of the disorder may require muscle relaxants, antidepressants and 
anxiolytics [4,7].  Cognitive behavioural therapy (CBT) as well as hypnotherapy have also been used 
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as psychological interventions.  However, these treatment options have shown limited efficacy, and 
many patients resort to complementary and alternative medicine (CAM), despite lack of evidence to 
support its use.  These include dietary interventions  and herbal preparations including peppermint 
oil and Aloe [8]. 
Aloe is a plant genus that belongs to the Asphodelaceae family.  They are perennial succulents, and 
characterized by long and thick fleshy leaves that are lance-shaped, with spiny margins and a sharp 
apex.  Although the genus originated in the dry and warm climates of Africa, Aloes are very adaptable 
and can be found worldwide.  Aloe leaves produce a yellow latex, referred to as Aloe sap.  The leaf 
pulp is composed of parenchyma cells that make up a gel [9].  
The gel and sap are extracted from the leaf, and it is these substances that are often used as 
treatment.  Previous research in rats suggests Aloe’s laxative and anti-inflammatory actions may have 
a beneficial effect in the treatment of constipation-predominant IBS [10,11,41], and research 
conducted on humans suggests it may be effective in treatment of inflammatory bowel disease 
symptoms[10,11].  Clinical trials have also been carried out to assess the effectiveness of Aloe in 
treating IBS symptoms among humans, however the evidence of its effects is limited and 
contradictory [12].  To date, the effectiveness of Aloe in treating IBS symptoms in clinical trials has 
not been systematically studied.  Therefore, the objective of this study is to summarize the existing 
evidence on the contribution of Aloe to improved health outcomes among patients diagnosed with 
IBS, and where possible, identify potential factors that may influence this response. 
2. AIM AND OBJECTIVES 
2.1.  AIM 
To evaluate the effect of Aloe on symptoms associated with Irritable Bowel Syndrome (IBS) in adults. 
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2.2.  OBJECTIVES 
To summarize the existing evidence on the contribution of Aloe to improved health outcomes among 
adult patients diagnosed with IBS and where possible, identify potential factors that may influence 
this response. 
Review Question 
Among adults diagnosed with irritable bowel syndrome, is the consumption of Aloe, compared with 
placebo, associated with improved health outcomes? 
2.  METHODS 
2.1.  Protocol and Registration 
This systematic review and meta-analysis protocol has been published in the PROSPERO International 
Prospective Register of systematic reviews [20], registration number CRD42018082663. 
2.2.  Search strategy 
The authors searched the medical literature using Medline, Scopus, EBM reviews, Africa-wide, 
CINAHL, Web of Science, Mednar, Cochrane Library, clinicaltrials.gov, World Health Organization 
Library Information System (WHOLIS), Ebscohost and grey literature (Google Scholar) up to August 
2018.  Randomized controlled trials of adults (>18 years) diagnosed with IBS based on diagnostic 
criteria (Manning or Rome iterations) were considered.  If studies induced constipation or other IBS-
related symptoms using drugs, such as opioids, these were excluded from the analysis.  In addition 
to randomized controlled trials (RCTs), the authors considered as eligible for inclusion non-
randomised controlled trials, retrospective and prospective cohort studies, and controlled before-
and-after (CBA) studies.  
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A comprehensive search strategy was developed to search both published and unpublished articles.  
These included peer-reviewed journal articles, conference proceedings and grey literature (including 
unpublished, internal or non-reviewed papers and technical reports).  The strategy included MeSH 
and free-text terms relating to IBS and Aloe literature.  No language restrictions were applied.  The 
lead reviewer evaluated the titles and abstracts of papers identified by the initial search for 
appropriateness to the study question.  Potentially relevant papers were downloaded and reviewed 
in detail.  Two reviewers independently assessed pre-selected articles using predesigned data 
extraction forms according to pre-defined eligibility criteria.  Any disagreement between 
investigators was resolved by consensus. 
Table 1 details the search strategy used for PubMed.  This strategy was adapted to suit individual 
databases using applicable vocabulary and syntax.   
2.3. Types of interventions 
For this review, the term ‘Aloe’ was used to denote any species of Aloe either in its natural form or 
in any commercially-available forms, including those used in conjunction with other compounds. Aloe 
was included in its different forms as a therapeutic intervention to address symptoms related to IBS.  
These included patients who had received conventional medications in addition to Aloe, as well as 
those who were no longer taking any conventional medication and were seeking further treatment.  
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Table 1: PubMed search strategy, modified as needed for use in other databases 
 Subject/ Related term Search Terms 
PubMed search strategy 
#1 Intestinal diseases, colonic 
diseases, irritable bowel 
syndrome, gastrointestinal 
motility, irritable colon, 
peristalsis, constipation, 
diarrhea, feces, stool, 
abdominal pain, bloating, 
defecation, laxatives, 
bulking agent, dysmotility, 
visceral hypersensitivity, 
spastic colon, Rome 
criteria  
intestinal diseases"[MeSH Terms] OR "colonic diseases"[MeSH Terms]) OR 
"irritable bowel syndrome"[MeSH Terms]) OR irritable bowel 
syndrome[Title/Abstract]) OR "gastrointestinal motility"[MeSH Terms]) OR 
"irritable bowel syndrome"[MeSH Terms]) OR irritable colon[Text Word]) OR 
"peristalsis"[MeSH Terms]) OR peristalsis[Title/Abstract]) OR 
"constipation"[MeSH Terms]) OR constipation[Text Word]) OR "diarrhea"[MeSH 
Terms]) OR diarrhea[Text Word]) OR "feces"[MeSH Terms]) OR stool[Text 
Word]) OR "feces"[MeSH Terms]) OR feces[Text Word]) OR abdominal 
pain[Title/Abstract]) OR abdominal pain[Text Word]) OR "defecation"[MeSH 
Terms]) OR defecation[Text Word]) OR "laxatives"[MeSH Terms]) OR 
laxative[Title/Abstract]) OR bulking agent[Title/Abstract]) OR dysmotility[Text 
Word]) OR visceral hypersensitivity[Text Word]) OR spastic 
colon[Title/Abstract]) OR spastic colon[Text Word]) OR Rome criteria[Text 
Word]) OR bloating[Title/Abstract]) OR "abdominal pain"[MeSH Terms]) OR 
abdominal pain[Title/Abstract] 
#2 Xanthorrhoeaceae, Aloe, 
Asphodelaceae, Aloeaceae, 
Aloeandongensis, 
Aloedent, Aloe emodin, 
aloe*, emodin, barbaloin 
"xanthorrhoeaceae"[MeSH Terms] OR Xanthorrhoeaceae[Text Word]) OR 
"aloe"[MeSH Terms]) OR (aloe[Title/Abstract] OR aloe'[Title/Abstract] OR 
aloe's[Title/Abstract] OR  "Asphodelaceae"[MeSH Terms] OR 
Asphodelaceae[Text Word] OR aloeaceae[Title/Abstract] OR 
aloeandongensis[Title/Abstract] OR aloedent[Title/Abstract] OR “aloe 
emodin”[Title/Abstract] OR aloei[Title/Abstract] OR aloeicola[Title/Abstract] OR  
aloemannan[Title/Abstract] OR aloemodin[Title/Abstract] OR 
aloenin[Title/Abstract] OR aloepecia[Title/Abstract] OR aloeresin[Title/Abstract] 
OR aloeride[Title/Abstract] OR aloes[Title/Abstract] OR aloes'[Title/Abstract] OR 
aloesin[Title/Abstract] OR aloesinol[Title/Abstract] OR aloesol[Title/Abstract] OR 
aloesone[Title/Abstract] OR aloesorb[Title/Abstract] OR 
aloespanoarin[Title/Abstract] OR aloestron[Title/Abstract] OR 
aloeswood[Title/Abstract] OR aloethanes[Title/Abstract] OR 
aloetic[Title/Abstract] OR aloetica[Title/Abstract] OR aloeticola[Title/Abstract] 
OR aloetron[Title/Abstract] OR aloeus[Title/Abstract] OR aloev[Title/Abstract] 
OR aloeVera[Title/Abstract] OR aloeVerae[Title/Abstract] OR 
aloeverose[Title/Abstract] OR aloexylon[Title/Abstract])) OR Aloctin[Text Word]) 
OR aloin[Title/Abstract]) OR aloin[Text Word]) OR "emodin"[MeSH Terms]) OR 
emodin[Text Word]) OR barbaloin[Text Word] 
Search  #1 AND #2 
Filters: Publication date from 1970 to 31 August 2018 
2.4. Outcome assessment 
The primary outcomes assessed were the efficacy of Aloe compared with placebo on global IBS 
symptoms after treatment, including patients’ improvement of symptoms or self-reported quality of 
life.   These included various self-reported measurement scales such as the Gastrointestinal 
Symptoms Rating Scale (GSRS), visual analogue scale (VAS), EuroQol (EQ5D), Short Form 12 (SF12) 
and Short Form 36 (SF36) quality of life questionnaires.  This choice of primary outcome is in keeping 
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with most studies reported to date.  Any adverse events in the selected studies were also reported 
on and summarized.  
Two reviewers (FF and IS) independently extracted data onto a Microsoft Word data extraction form.  
The following data was extracted for each trial: Study design, setting, type and form of intervention 
(including dose), duration of treatment, IBS diagnosis criterion used, and primary and secondary 
outcome measures.   
2.5. Study quality 
Two reviewers (FF and IS) assessed study quality independently according to the Cochrane tool for 
Risk of Bias assessment.  This assessed aspects of study included selection bias (dealing with 
confounding, adjustment and comparability of groups), performance bias (in terms of the ﬁdelity of 
the interventions); detection bias (regarding unbiased and correct assessment of outcomes, including 
blinding of assessors); attrition bias (with regard to completeness of sample, follow-up and data); and 
reporting bias (with regard to publication biases and selective reporting of results). Studies were 
scored as having low, moderate or high risk of bias.  
2.7. Data synthesis and statistical analysis 
The individual study authors’ assessments were used as to what constituted a response to treatment 
in order to recode trial data into a dichotomous outcome of response versus non-response to 
treatment.  Where necessary, the authors of the selected studies were contacted for missing data.  If 
the authors are not able to respond, or if they could not provide the data requested, missing data 
was indicated in the review. 
Data was pooled using a random effects model to give a more conservative estimate of the effect of 
individual treatments, allowing for heterogeneity between studies.  The effects of different 
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interventions were expressed as a Risk Ratio with 95% confidence interval (CI) of global symptoms of 
irritable bowel syndrome persisting with Aloe compared with placebo.  Statistical heterogeneity in 
each meta-analysis was assessed using the χ2 test and quantiﬁed using the 𝐼2 statistic with a cut-off 
point of 25% to assess heterogeneity between studies.  It was planned to do sub-group analysis 
according to IBS sub-type.  The ﬁnal data was analysed with Review Manager V.5.3 statistical software 
[43], and references were managed using the Mendeley citation manager [44].  
3. RESULTS 
The search strategy generated 2,386 citations, and an additional 13 articles were identified separately 
through snowballing and random searches in Google scholar.  Out of this total, 139 were duplicates 
and the remaining 1974 were potentially relevant and retrieved for assessment.  Of these, 1,948 were 
excluded and the remaining 26 studies were assessed for full-text eligibility.  The full-text assessment 
resulted in six eligible RCTs, which compared Aloe or Aloe in combination with other compounds with 
placebo.  The PRISMA diagram in Figure 1 shows the flow of information through the various phases 
of the systematic review. It maps the number of records identified, included and excluded, as well as 
those that were finally included in the meta-analysis.  
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Figure 1: PRISMA diagram showing flow of information through the various phases of the systematic review 
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3.1.  Characteristics of included studies 
Table 1 provides a summary of the studies included in this review.  Six studies, comprising 435 
participants were included in this systematic review.  Studies were conducted in China (1 study, 84 
participants), Israel (2 studies, 115 participants), Sweden (1 study, 68 participants) and the United 
Kingdom (2 studies, 168 participants).  Participants’ age ranged from 18 to 81 years of age, diagnosed 
with IBS or functional constipation through the Manning and Rome criteria (Rome iterations include 
Rome I, Rome II and Rome III).  Interventions included: 50ml Aloe drink, prescribed four times daily 
for one month; 60ml Aloe drink prescribed two times daily for five months (followed by a two-week 
washout period after which placebo and experimental groups would be crossed-over); 105mg 
Traditional Chinese Medicine capsule, containing Aloe extract; 500mg of celandin, Aloe Vera and 
psyllium in the ratio of  6:3:1 (i.e. 150mg Aloe Vera), where  initial dose was 1 capsule per day and 
increasing to 3 capsules per day depending on response; and 250mg Aloe Extract + 60mg ascorbic 
acid effervescent tablets dissolved in water two times daily for one month. Comparison interventions 
were placebo, matched in appearance and other characteristics.  One study [17] incorporated 
multiple arms, of which those relevant to this study’s inclusion criteria were included.  Another study 
[16] was a crossover RCT, but unfortunately no data was available to include in the meta-analysis. 
Information on the characteristics of studies included in this systematic review is shown in Table 2. 
13 
 
Table 2: Characteristics of included studies 
Study ID 
Study 
design 
Country Population Intervention Control group Outcome 
Davis, Philpott, 
Kumar & 
Mendall 2006 
[15] 
RCT UK 
Patients aged 18-65;  
diagnosed with IBS 
by Rome II 
Aloe Vera (NLP formulation);   
50ml 4 times daily; 1-month duration 
Matching 
placebo   
Improvement of symptoms through global summated score of 500 
points with a ≥50 point improvement considered as response to 
treatment.   Patients assessed at end of treatment, and 3 months 
post treatment. 
Hutchings et 
al., 2011 [16] 
RCT 
(cross-
over) 
UK. 
Patients aged 18 and 
older, diagnosed with 
IBS by Rome II for at 
least one year.  
 
Aloe Vera drink 60ml 2 times daily; 5 
months duration for 5 months followed 
by 2 weeks wash out and then crossed 
over 
Matching 
placebo 
Improvement of patient quality of life. Four self-reported quality of 
life scales were used in the study including EQ5D, GSRS, SF12 
and IBSQOL.  Response to treatment was not defined by authors.  
Patients assessed at end of each study cross-over period, each 
lasting 5 months. 
Jia et al., 2010 
[17] 
RCT 
(3-arm 
study) 
China 
Patients aged 18-65. 
Diagnosed with 
functional 
constipation by Rome 
III 
70mg of Yun-chang capsule plus 35mg 
placebo (group A), 105mg of Yun-
chang capsule (group B), 3 times daily 
for 2 weeks.  
Matching 
placebo for 
Group C 
(105mg of 
placebo). 
 
Improvement of symptoms using two rating scales to rate 
symptoms: main symptoms included stool frequency, consistency 
and dyschezia, and were rated using 7-point scale.  Distension, 
dry mouth and throat, weakness and hectic fever were scored 
through 4-point scale. Response to treatment was defined as 
change in main symptom scores and cumulative symptom scores 
2 weeks following treatment. 
Odes & Madar, 
1991 [18] 
RCT Israel 
Patients aged 18 and 
older with 
constipation for over 
two years or 
diagnosed with IBS-C 
by unspecified 
criteria. 
500mg capsule of Celandine, Aloe 
Vera and Psyllium in the ratio of 6:3:1 
(i.e. 150mg Aloe Vera).  Initial dose 
was 1 capsule per day and increasing 
to 3 times daily depending on response 
Matching 
placebo  
Improvement of symptoms (incl. stool rate, and consistency, 
abdominal pain, distension).  Response to treatment was defined 
by patients as to whether they regarded themselves as improved 
following treatment. 
Sallon et al., 
2002 [19] 
RCT Israel 
Patients aged 20-81. 
Diagnosed with IBS-C 
by Rome I and 
international 
consensus criteria for 
constipation. 
482mg of Padma Lax formula 
(containing 12.5mg of Aloe extracts 
taken 2 times daily for 3 months. 
Matching 
placebo 
Improvement of symptoms. The patients compared their overall 
response to the trial therapy with previous treatments tried for 
IBS-C using ordinal scale: 0 (worse), 1 (same), 2 (better) and 3 
(much better). Patients were also asked at each monthly visit to 
state their overall impression of any positive effect of treatment.  
Response to treatment was not defined by authors. 
Størsrud et al., 
2015 [14] 
RCT Sweden 
Patients aged 18-65. 
Diagnosed with IBS 
by Rome III 
Aloe Vera Extract effervescent tablets 
(250mg AVH200® + 60mg ascorbic 
acid and excipients) dissolved in water 
2 times daily; 1 month duration 
Matching 
placebo  
Improvement of symptoms through the use of the IBS symptom 
severity scoring system (IBS-SSS), with range 0-500, with a ≥50 
point improvement considered as response to treatment.   
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3.2.  Excluded Studies 
Twenty studies [19-38] were excluded during the full-text screening phase.  The reasons for exclusion 
are summarized in Table 3.  One study [35] was excluded by the main author on account of having 
been published later in a different journal [14], and which was considered for inclusion as shown in 
Table 1. 
Table 3: Table of excluded studies 
Study ID Reason for exclusion 
Bhaludra et al., 2013 [17] Review study – no primary data provided 
Chang and Lu, 2009 [18] Review study – no primary data provided 
Cirillo and Capasso 2015 [19] Review study – no primary data provided 
Franz, 1992 [20] Full text article could not be accessed 
Flück 1970 [21] Full text article could not be accessed 
Gordon et al., 2016 [22] Review study – no primary data provided 
Hu, 2009 [23] Constipation was induced by opioids 
Hutcheon, 2014 [24] Review study – no primary data provided 
Khedmat et al., 2013 [25] Before-and-after study (not placebo-controlled) 
Koch, 1993 [26] Before-and-after study (not placebo-controlled)  
Jekat, 1990 [27] Review study – no primary data provided 
Koch, 1995 [28] Full text article could not be accessed 
Kwon and Sun, 2016 [29] Constipation was induced by opioids 
Liu et al., 2006 [30] Review study – no primary data provided 
Ma, 2015 [31] Constipation was induced by opioids 
Melzig, 2008 [32] Full text article could not be accessed 
Størsrud et al., 2009 [33] Previously published duplicate of a selected study [14] 
Wintola, 2017 [34] Ethno-botanical study with no primary experimental data  
Wiessner, 2008 [35] Full text article could not be accessed 
Zhao et al., 2004 [36] Constipation was induced by opioids 
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3.3. Quantitative data synthesis 
3.3.1.  Effect of Aloe on improving IBS symptoms among all IBS sub-types  
Compared with placebo, all Aloe (Aloe only and/or Aloe combined) improved symptoms in IBS 
patients (all subtypes) (RR, 2.75 (95% CI 1.88 to 4.03), 5 studies, n=325, I2=0%) (Figure 2).   
 
3.3.2.   Effect of Aloe (Aloe only) on improving IBS symptoms among all IBS sub-types.   
Compared with placebo, Aloe (Aloe only) improved symptoms with all subtypes of IBS (RR, 1.89 (95% 
CI, 1.01 to 3.56); 2 studies, n= 126; I2=0%) (Figure 3). 
 
 
  
Figure 2:  Aloe (all types) for improving IBS symptoms (All IBS subtypes) 
Figure 3:  Aloe (only) for improving IBS symptoms (All IBS subtypes) 
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3.3.3.  Effect of Aloe (Aloe combined) on improving IBS symptoms among constipation-
predominant IBS (IBS-C) patients only  
Compared with placebo, Aloe (Aloe combined) improved symptoms in IBS-C patients (RR, 3.41 (95% 
CI 2.11 to 4.03), 3 studies, n=199, I2=0%) (Figure 4)  
3.3.4.   Effect of Aloe on improving Diarrhoea-predominant IBS symptoms (IBS-D and IBS-M) 
The single study [13] amongst IBS-D and IBS-M patients, failed to demonstrate effectiveness of Aloe 
(Aloe only) in relieving symptoms. 
3.4.   Assessment of risk of bias in included studies 
Assessment of risk of bias was done using the Cochrane Risk of Bias tool.  Of the studies assessed, 
two were deemed as having high risk of bias due to attrition.   Two studies indicated random 
sequence generation, while the remaining studies did not provide this information.  Four studies 
made clear mention of allocation concealment, while two did not provide details.  Two studies 
reported a high number of dropouts and their risk of attrition bias was ranked as high. Two studies 
provided details on blinding of outcome assessment and the remaining four did not.  Table 3 shows 
the summary of risk of bias assessment.  Number studies were deemed as being of high risk of bias 
(reference of study).  
 
Figure 4:  Aloe (Aloe combined) for improving symptoms among constipation-predominant IBS patients 
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Table 4: Summary of risk of bias assessment using the Cochrane tool 
Study ID 
Risk of 
bias 1 
Risk of 
bias 2 
Risk of 
bias 3 
Risk of 
bias 4 
Risk of 
bias 5 
Risk of 
bias 6 
Risk of 
bias 7 
Risk of bias 
Davis et al., 2006 
[15] 
+ + + ? - ? ? High risk of bias 
Hutchings 2011 
[16] 
? ? ? ? - ? ? High risk of bias 
Jia et al., 2010 
[17] 
+ + + ? + ? ? Moderate risk of bias 
Odes & Madar 
1991 [18] 
? ? ? ? + + ? Moderate risk of bias 
Sallon et al., 2002 
[19] 
? + + + + + ? Moderate risk of bias 
Størsrud et al., 
2015 [14] 
? + ? + + + ? Moderate risk of bias 
Bias 1: Random sequence generation (selection bias) 
Bias 2: Allocation concealment (selection bias) 
Bias 3: Blinding of participants and personnel (performance bias) 
Bias 4: Blinding of outcome assessment (detection bias) 
Bias 5: Incomplete outcome data (attrition bias) 
Bias 6: Selective reporting (reporting bias) 
Bias 7: Other bias 
 
3.5.   Adverse events 
Cases of adverse events were reported by three trials [12,15,37].  Given that these were few in 
number, the data were not pooled.  One was the three-arm study [15] and the only adverse events 
were reported in Group A, which was not considered for the meta-analysis.  This was the case of one 
patient developing diarrhoea, accompanied by abdominal pain after which the patient was advised 
to reduce dosage and the symptoms receded.   
Another study that dealt specifically with IBS-C patients [37], reported that 10 out of the 34 patients 
in the experimental group had complained of mild side effects.  These included 1 patient with nausea, 
1 with a slight headache and 1 with hoarseness.  In addition, 7 patients developed loose stools or 
diarrhoea, including 1 patient who also complained of a mild episode of shortness of breath, dizziness 
and chest pain, which was resolved within 24 hours.  According to the protocol, patients who 
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developed diarrhoea were to lower their dose by half.  In the placebo group, 5 out of 27 patients 
reported side effects including 2 with abdominal pain, 1 with nausea and 2 with heartburn. 
In the third study that reported cases of adverse events, only 1 out of the 33 patients in the 
experimental group reported minor haemorrhoidal rectal bleeding, after which he withdrew from 
the study.  After the study, this patient reported that he had occasional rectal bleeding five years 
before the study and that the current bleeding had stopped three days after he had stopped taking 
the Aloe and was not different from previous bleeding episodes.  No adverse events were reported 
in the placebo group.  All in all, when taking into consideration those studies included in the meta-
analysis, 11 out of 168 (6%) in the experimental groups, and 5 out of 157 patients (3%) were reported 
to have developed mild side effects. 
4.    DISCUSSION 
4.1.   Principal Findings 
This systematic review found statistically significant evidence for Aloe-containing preparations being 
more effective than placebo in improving IBS symptoms overall.  This finding was especially 
pronounced amongst IBS-C patients, regardless of the nature of the Aloe preparation.  Among 
patients with diarrhea-predominant IBS (IBS-D), however, there is no evidence of Aloe’s effectiveness 
in improving symptoms.   This work provides the first attempt at a systematic approach to 
summarizing the evidence of the effectiveness of Aloe in alleviating IBS symptoms. 
Laxatives are considered a primary measure for the treatment of IBS-C and functional constipation.  
The finding of Aloe’s effectiveness in improving constipation symptoms may be explained by Aloe’s 
laxative properties, which in turn, supports the biological plausibility of this finding.  However, 
although laxatives such as Aloe have been shown to improve stool frequency, they have no proven 
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effect on other symptoms such as bloating and abdominal pain [15].  Thus, it is possible that the effect 
of Aloe in relieving abdominal pain is indirect, in that improving stool frequency can lead to reduced 
pain.  It is also worth noting that in some of the studies, participants were advised to alter their dosage 
depending on the symptoms experienced.  This suggests that the optimal aloe dosage may differ in 
IBS sub-types, although it may require further investigation. 
It was initially thought that, because people considered CAM to be more effective than conventional 
medicine in treating IBS symptoms, the placebo effect would be larger in CAM clinical trials. A meta-
analysis comparing CAM treatments for IBS to placebo have found a rather high pooled placebo 
response rate greater than 40%. However, when compared with the placebo response rate in 
conventional medicine trials for IBS, the response rate is similar.  This suggests that the placebo 
response rate is not dependent on the type of therapy used, and that it may not be “enhanced” as 
initially thought by the use of CAM [38].   
4.2.   Study limitations 
This systematic review employed a detailed search strategy in sourcing relevant articles; however, 
considering the widespread use of Aloe, one surprising finding was the paucity of controlled clinical 
trials. In addition, high attrition rates were evident in two the selected studies [13,14], one of which 
was included in the meta-analysis [13].  However, the effect of attrition in this study appears to be 
negligible, given that the direction of effect was congruent with the other studies in the meta-
analysis, as reflected by the low heterogeneity. 
Another limitation was the lack of access to non-English journals, especially in Chinese as these could 
only be accessed through Chinese academic institutions.  There was also the challenge of dealing with 
the different ways in which study authors defined response to treatment.  Some studies employed 
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continuous scales to rate improvement of symptoms, while others use ordinal scales, all with 
differences in value ranges.  In some studies, only a ≥10% improvement in symptoms was considered 
a response to treatment, while in others a ≥50% improvement in symptoms was considered 
adequate.  Thus, the methods used to assess effect estimates were not standardized. More 
methodological consistency ought to be considered when designing and carrying out clinical trials 
involving IBS patients.  Furthermore, given the variations in formulae of Aloe preparations in the 
included studies, standardized formulations would be desirable.  Nevertheless, the meta-analysis 
found low heterogeneity amongst the studies. 
5.     CONCLUSION 
5.1.   Implications for further research 
Aloe-containing preparations were more effective than placebo in improving symptoms among all 
IBS sub-types combined.  In sub-group analyses, Aloe was more effective than placebo in the 
treatment of constipation-predominant IBS, however this was not the case with IBS-D and IBS-M sub-
types. Given the variation in the formulae of Aloe preparations in the included studies, 
generalizability of this finding may be a challenge.  Thus, further research with adequately-powered 
studies using a standardised formulation for Aloe-containing preparations for IBS is advised.  
While this review has demonstrated sufficient evidence for the use of Aloe in IBS-C, there remains 
nevertheless, a dearth of knowledge on further IBS-subtypes.  This work highlights the need for 
applying methodological consistency in further studies, including (1) Standardized methods of 
assessing response to treatment and (2) Standardized symptom rating scales.  In addition, 
adequately-powered studies are warranted especially when considering the high patient attrition 
rates in some of the reviewed studies.  
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5.2.   Implications for clinical practice 
The complex and heterogeneous nature of IBS suggests that instead of using one single agent, it may 
be more effective to use a combination of agents directed at treating each individual symptom [14].  
When comparing effect size between those studies that used Aloe by itself with those that used Aloe 
in combination with other agents, a much stronger effect was visible in the latter.  This could be due 
to the multi-symptom nature of IBS and how the other agents were able to address each symptom 
more effectively.      
In conclusion, the results suggest that Aloe may be a safe and effective treatment for patients with 
IBS-C.  However, for patients with IBS-D and remaining IBS sub-types, further large trials are 
warranted. 
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APPENDIX 1: PRISMA 2009 CHECKLIST (For Manuscript) 
Section/topic  # Checklist item  
Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  2 
ABSTRACT   
Structured summary  2 
Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
5 
METHODS   
Protocol and registration  5 
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
6 
Eligibility criteria  6 
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
8 
Information sources  7 
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in 
the search and date last searched.  
6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  7 
Study selection  9 
State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
9 
Data collection process  10 
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
8 
Data items  11 
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
9 
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Risk of bias in individual studies  12 
Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study 
or outcome level), and how this information is to be used in any data synthesis.  
8-9 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  9 
Synthesis of results  14 
Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each 
meta-analysis.  
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Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
17 
Additional analyses  16 
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
15-16 
RESULTS   
Study selection  17 
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
12 
Study characteristics  18 
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
13 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  17 
Results of individual studies  20 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
15-16 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  15-16 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  17 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  15-16 
DISCUSSION   
Summary of evidence  24 
Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
18-19 
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Limitations  25 
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
19 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  20 
FUNDING   
Funding  27 
Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
21 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
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APPENDIX 2: Comprehensive Search Strategy 
 Subject/ Related term Search Terms 
PubMed search strategy 
#1 Intestinal diseases, colonic 
diseases, irritable bowel 
syndrome, gastrointestinal 
motility, irritable colon, 
peristalsis, constipation, 
diarrhea, feces, stool, 
abdominal pain, bloating, 
defecation, laxatives, bulking 
agent, dysmotility, visceral 
hypersensitivity, spastic colon, 
Rome criteria  
intestinal diseases"[MeSH Terms] OR "colonic diseases"[MeSH Terms]) OR "irritable bowel 
syndrome"[MeSH Terms]) OR irritable bowel syndrome[Title/Abstract]) OR "gastrointestinal 
motility"[MeSH Terms]) OR "irritable bowel syndrome"[MeSH Terms]) OR irritable colon[Text Word]) 
OR "peristalsis"[MeSH Terms]) OR peristalsis[Title/Abstract]) OR "constipation"[MeSH Terms]) OR 
constipation[Text Word]) OR "diarrhea"[MeSH Terms]) OR diarrhea[Text Word]) OR "feces"[MeSH 
Terms]) OR stool[Text Word]) OR "feces"[MeSH Terms]) OR feces[Text Word]) OR abdominal 
pain[Title/Abstract]) OR abdominal pain[Text Word]) OR "defecation"[MeSH Terms]) OR 
defecation[Text Word]) OR "laxatives"[MeSH Terms]) OR laxative[Title/Abstract]) OR bulking 
agent[Title/Abstract]) OR dysmotility[Text Word]) OR visceral hypersensitivity[Text Word]) OR spastic 
colon[Title/Abstract]) OR spastic colon[Text Word]) OR Rome criteria[Text Word]) OR 
bloating[Title/Abstract]) OR "abdominal pain"[MeSH Terms]) OR abdominal pain[Title/Abstract] 
#2 Xanthorrhoeaceae, Aloe, 
Asphodelaceae, Aloeaceae, 
Aloeandongensis, Aloedent, 
Aloe emodin, aloe*, emodin, 
barbaloin 
"xanthorrhoeaceae"[MeSH Terms] OR Xanthorrhoeaceae[Text Word]) OR "aloe"[MeSH Terms]) OR 
(aloe[Title/Abstract] OR aloe'[Title/Abstract] OR aloe's[Title/Abstract] OR  "Asphodelaceae"[MeSH 
Terms] OR Asphodelaceae[Text Word] OR aloeaceae[Title/Abstract] OR 
aloeandongensis[Title/Abstract] OR aloedent[Title/Abstract] OR “aloe emodin”[Title/Abstract] OR 
aloei[Title/Abstract] OR aloeicola[Title/Abstract] OR  aloemannan[Title/Abstract] OR 
aloemodin[Title/Abstract] OR aloenin[Title/Abstract] OR aloepecia[Title/Abstract] OR 
aloeresin[Title/Abstract] OR aloeride[Title/Abstract] OR aloes[Title/Abstract] OR aloes'[Title/Abstract] 
OR aloesin[Title/Abstract] OR aloesinol[Title/Abstract] OR aloesol[Title/Abstract] OR 
aloesone[Title/Abstract] OR aloesorb[Title/Abstract] OR aloespanoarin[Title/Abstract] OR 
aloestron[Title/Abstract] OR aloeswood[Title/Abstract] OR aloethanes[Title/Abstract] OR 
aloetic[Title/Abstract] OR aloetica[Title/Abstract] OR aloeticola[Title/Abstract] OR 
aloetron[Title/Abstract] OR aloeus[Title/Abstract] OR aloev[Title/Abstract] OR 
aloeVera[Title/Abstract] OR aloeVerae[Title/Abstract] OR aloeverose[Title/Abstract] OR 
aloexylon[Title/Abstract])) OR Aloctin[Text Word]) OR aloin[Title/Abstract]) OR aloin[Text Word]) OR 
"emodin"[MeSH Terms]) OR emodin[Text Word]) OR barbaloin[Text Word] 
  
Search  #1 AND #2 
Filters: Publication date from 1970 to 31 August 2018 
 
 Subject/ Related term Search terms 
Scopus search strategy 
#1 Intestinal diseases, colonic 
diseases, irritable bowel 
syndrome, gastrointestinal 
motility, irritable colon, 
peristalsis, constipation, 
diarrhea, feces, stool, 
abdominal pain, bloating, 
defecation, laxatives, bulking 
agent, dysmotility, visceral 
hypersensitivity, spastic colon, 
Rome criteria  
(TITLE-ABS-KEY ( "Intestinal diseases"  OR  "colonic diseases"  OR  "irritable bowel syndrome"  OR  
"gastrointestinal motility"  OR  "irritable colon"  OR  "peristalsis"  OR  "constipation"  OR  "diarrhea"  
OR  "diarrhoea" OR feces"  OR  "stool" )  OR  TITLE-ABS-KEY ( "defecation"  OR  "laxative"  OR  "bulking 
agent"  OR  "dysmotility"  OR  "visceral hypersensitivity"  OR  "spastic colon"  OR  "Rome criteria"  OR  
"Bloating"  OR  "Abdominal pain"  OR  "Functional" ) )   
#2 Xanthorrhoeaceae, Aloe, 
Asphodelaceae, Aloctin, 
Aloeaceae, Aloin, Aloedent, 
emodin, barbaloin 
( TITLE-ABS-KEY ( "Xanthorrhoeaceae"  OR  "Aloe"  OR  "asphodelaceae" OR "aloctin"  "aloeaceae" OR  
"aloin"  OR  "aloedent" OR "emodin"  OR  "barbaloin" )  ) 
  
Search #1 AND #2 
Filters: Publication date from 1970 to 31 August 2018 
Note: Search terms were also adapted to suit other individual databases using applicable syntax and vocabulary.  These 
included EBM reviews, Global Health and International Pharmaceutical Abstracts, CINAHL, Web of Science, Mednar, Cochrane 
Central Register of Control Trials, Pan African Clinical Trials Register, clinicaltrials.gov, World Health Organization Library 
Information System (WHOLIS) and Ebscohost. 
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APPENDIX 3: Data Extraction Form 
Review Title: 
Consumption of Aloe to improve health outcomes in adults with irritable 
bowel syndrome:  A systematic review and meta-analysis.  
Study ID 
(e.g. Lopez, 2017) 
 
Full article title 
 
 
I. General information 
Date form completed 
(dd/mm/yyyy) 
 
Name of person extracting 
data 
 
Full reference citation (i.e. full 
reference citation, Harvard 
style() 
 
Study author contact details 
(e.g. E-mail, phone) 
 
Publication type (e.g. full 
report, abstract) 
 
Bibliography hand search, 
(i.e. References for possible 
eligible studies) 
 
Notes: 
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II. Study Eligibility  
Study Characteristics Eligibility criteria Eligibility criteria met? 
Types of study RCT, CCT, CBA, Before-and-after, 
Quasi-randomised trial, cross-
over study, cohort study, 
Observational study, letter to 
editor of journal  
Yes    No     
Unclear   (Specify below) 
 
Participants  
Including adults >= 18 years of 
ages 
Yes    No   
Unclear  (specify below) 
 
Types of Outcome measure  
Primary outcome (please specify 
below):  
 
Yes    No   
Unclear  (specify below) 
 
INCLUDE                       EXCLUDE                                      PENDING  
 
Reason for 
exclusion/pending?  
 
 
Notes: 
 
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
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III. Characteristics of the Study 
 Descriptions as stated in report/paper 
Aim of study   
Start date  
End date  
Total duration of study  
Type of intervention/exposure  
Was sequence generation 
conducted? If yes, how? 
 
Was allocation concealment 
conducted? If yes, how? 
 
Was Blinding conducted? If yes, 
how? 
 
Describe in general terms the 
reported measure/s used for 
primary outcome (e.g. Health-
related quality of life (HRQoL) 
self-assessment questionnaire, 
visual analogue scale, etc.)  
 
 
Country, language   
Ethical approval needed/ 
obtained for study 
 
Yes    No           Unclear  
      
Notes: 
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IV. Participants  
 Descriptions as stated in report/paper 
Country   
Population description  
Condition being addressed 
through the intervention (e.g. 
IBS, constipation, diarrhoea)  
 
Inclusion criteria / Diagnostic 
criteria (e.g. Rome criteria) 
 
Exclusion criteria  
Method of recruitment of 
participants (e.g. mail, phone, 
existing records, in-hospital) 
 
Site of recruitment of 
participants (e.g. hospital/ 
health facility) 
 
Selection methods (e.g. 
randomized) 
 
Initial recruited sample size  
Intervention group Control/Placebo group 
  
Loss to follow up 
Intervention group Control/Placebo group 
  
Final participant count 
Intervention group Control/Placebo group 
  
Age(s)  
Gender  
Ethnicity  
Data source (e.g. medical, 
interviews, surveys) 
 
Notes:  
 
 
 
 
 
10 
 
V. INTERVENTION CHARACTERISTICS 
Intervention: Aloe to treat IBS-related symptoms 
Details of intervention (e.g. aloe 
pills, gel or aloe in combination 
with other compounds) and 
dose 
 
Details of co intervention (if any) 
in all groups 
 
Delivery of intervention   (e.g. 
stages, timing, frequency, 
duration) 
 
Fidelity/integrity  
(Was the intervention delivered 
as intended? Record any 
assessment of this) 
 
Other remarks  
VI. Control or placebo group:  
Details of control/ placebo 
group  
 
Placebo substance provided  
Frequency  
Other remarks  
VII. Outcomes 
Primary Outcome: Self-reported quality of life/ improvement of symptoms 
 
Description of primary 
outcome and scale used to 
measure it  
 
Primary outcome:  
Intervention % Control % Difference P-value 
      
Age-group Breakdown 
       
       
Secondary Outcomes in the study (if any) 
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Description of secondary 
outcome and scale used to 
measure it 
Secondary outcome: Intervention % Control % Difference P-value
Age-group Breakdown 
VIII. Discussion
Descriptions as stated in report/paper 
Key conclusions of study 
authors 
Study Limits as reported by 
authors 
Recommendations 
Notes: 
IX. Other Information
Study funding sources 
Possible conflicts of interest 
(For study authors) 
Missing data 
Statistical methods and their 
appropriateness (if relevant) 
Correspondence required for further 
study information 
 
Notes:   
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APPENDIX 4: Ethics Waiver 
Signature Removed
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APPENDIX 5: Plos ONE Submission Guidelines for Authors 
